HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CPSC chair

This article was originally published in The Tan Sheet

Executive Summary

Consumer Product Safety Commission could receive a new head by May 1. Senate Commerce Committee nomination hearing for Harold Stratton was held April 25; Sens. Byron Dorgan (D-N.D.) and Ron Wyden (D-Ore.) questioned Stratton about free-market stands he has taken to protect businesses from government interference. Stratton appeared to satisfy concerns, though, noting as AG of New Mexico, he oversaw state's only consumer protection agency. Committee likely will send nomination to Senate for full vote; deadline to fill CPSC post is May 1, which signals expiration of six-month quorum period for two commissioners. Stratton's smooth hearing contrasts with that of President Bush's original nominee, Mary Sheila Gall, who faced stiff opposition from committee Democrats (1"The Tan Sheet" Aug. 6, 2001, p. 6)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel